A multicenter study with ketotifen (Zaditen).
Seven hundred and thirty-three atopic asthmatic patients were entered into two multicenter double-blind double-placebo controlled studies comparing the prophylactic effects of ketotifen (445 patients), placebo (143 patients), disodium cromoglycate (72 patients) and theophylline (73 patients). The primary measure of therapeutic effects was a decrease in concomitant medication without a significant increase in symptomatology or a decrement in pulmonary function: in both studies ketotifen was shown to be an effective and safe therapeutic agent at an oral dose of 1 mg bid. The positive control, DSCG, was also shown to be effective when used properly, while theophylline did not show a significant prophylactic effect.
D000284:Administration, Oral; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006801:Humans; D007665:Ketotifen / Q000627:therapeutic use*; D013806:Theophylline / Q000627:therapeutic use
D013806:Theophylline; D004205:Cromolyn Sodium; D007665:Ketotifen